Carisma Therapeutics Inc CARM

Healthcare Biotechnology

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.

NDAQ:CARM - Post by User

Carisma Therapeutics Inc > 4 BIOTECH STOCKS FACING FDA REJECTION!

<< Previous

Bullboard Posts

Next >>

Comment by floatinketuckyon Jan 24, 2022 6:51am

236 Views

Post# 34351317

RE:4 BIOTECH STOCKS FACING FDA REJECTION!

AviseAnalytics wrote:
4 BIOTECH STOCKS FACING FDA REJECTION!

Is it a full stop or a pause to their journey?

SESN FGEN SPPI ARDX

Read More:

https://www.aviseanalytics.com/4-biotech-stocks-facing-fda-rejection/
[url=https://www.aviseanalytics.com/4-biotech-stocks-facing-fda-rejection/
]Click Here[/url]